DHMEQ racemate (rel-DHMEQ) (Synonyms: rel-DHMEQ) |
Catalog No.GC33150 |
Le racémate DHMEQ (rel-DHMEQ) est un inhibiteur de NF-κB. Le racémate du DHMEQ (rel-DHMEQ) est moins actif que le (-)-DHMEQ.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 287194-38-1
Sample solution is provided at 25 µL, 10mM.
DHMEQ racemate is a NF-κB inhibitor. DHMEQ racemate is less active than (-)-DHMEQ.
DHMEQ racemate (DHM3EQ) and (-)-DHMEQ (DHM2EQ) inhibits TNF-a-induced NF-kB activation. (-)-DHMEQ is more potent and less toxic than DHMEQ racemate[1].
The antiarthritic effects of (-)-DHMEQ (DHM2EQ) and DHMEQ racemate (DHM3EQ) are examined on type-II collagen-induced arthritis in DBA1/J mice. This animal model is widely used for evaluation of antirheumatic drugs because of its pathological similarities to human rheumatoid arthritis. The arthritis is elicited and scored. (-)-DHMEQ markedly inhibits type-II-collagen-induced arthritis in mice, whereas DHMEQ racemate tends to only slightly inhibit it[1].
[1]. Matsumoto N, et al. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett. 2000 May 1;10(9):865-9.
Average Rating: 5
(Based on Reviews and 25 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *